Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11859421 | 1.00 | HRH3 (0.75) | HRH3CYP1A2MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL9158672 | 1.00 | HRH3 (0.75) | HRH3CYP1A2MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL7374716 | 1.00 | HRH3 (0.75) | HRH3CYP1A2MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1404041 | 1.00 | HRH3 (0.75) | HRH3CYP1A2MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1404023 | 1.00 | HRH3 (0.75) | HRH3CYP1A2MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1403869 | 1.00 | HRH3 (0.75) | HRH3CYP1A2MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1404107 | 1.00 | HRH3 (0.75) | HRH3CYP1A2MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4504898 | 0.97 | HRH3 (0.70) | HRH3CYP1A2MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL9078 | 0.97 | HRH3 (0.70) | HRH3CYP1A2MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1403845 | 0.97 | HRH3 (0.70) | HRH3CYP1A2MAPK1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112250866-B | Preparation method of free radical type photocuring resin with thioether as main chain | 江汉大学 | 2023-04-07 | — | — | CN | claimed |
| EP-2617779-B1 | Low odor environmentally-friendly nano-pigment inkjet ink composition | JETBEST CORP (TW) | 2014-11-05 | — | — | EP | claimed |
| US-8710118-B2 | Nano-pigment inkjet ink composition that has a low odor and is environmentally-friendly | JETBEST CORPORATION (TW) | 2014-04-29 | — | — | US | claimed |
| US-20130190421-A1 | LOW ODOR ENVIRONMENTALLY-FRIENDLY NANO-PIGMENT INKJET INK COMPOSITION | JETBEST CORPORATION (TW) | 2013-07-25 | — | — | US | claimed |
| EP-2617779-A1 | Low odor environmentally-friendly nano-pigment inkjet ink composition | JETBEST Corporation (TW) | 2013-07-24 | — | — | EP | claimed |
| EP-1399409-B1 | METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS | BASF SE (DE) | 2012-10-31 | — | — | EP | claimed |
| US-7026503-B2 | Method for producing (meth)acrylic acid esters | BASF AKTIENGESELLSCHAFT (DE) | 2006-04-11 | — | — | US | claimed |
| EP-1399408-B1 | METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS | BASF AG (DE) | 2006-03-22 | — | — | EP | claimed |
| WO-2025217125-A2 | NOVEL LIPIDS FOR DELIVERY OF NUCLEIC ACID THERAPEUTICS | POPVAX PRIVATE LIMITED (IN) | 2025-10-16 | — | — | WO | disclosed |
| WO-2023205615-A1 | ORALLY DISSOLVING ANTIMICROBIAL FILM COMPOSITIONS & METHODS OF THEIR USE | ISHA Therapeutics LLC (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| EP-4142787-A1 | METHODS AND COMPOSITIONS RELATING TO IONIC LIQUID ADJUVANTS | President And Fellows Of Harvard College (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2022271537-A1 | COMPOSITIONS AND METHODS RELATING TO INJECTABLE MICROEMULSIONS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-12-29 | — | — | WO | disclosed |
| EP-1053247-A1 | ANTIFUNGAL CYCLOHEXAPEPTIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-22 | — | — | EP | disclosed |
| US-5945426-A | PREVENT NEURONAL DEATH | NIPPON SHINYAKU CO., LTD. (JP) | 1999-08-31 | — | — | US | disclosed |
| WO-1999040108-A1 | NEW COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-12 | — | — | WO | disclosed |
| EP-0781766-A1 | HETEROCYCLIC DERIVATIVE AND MEDICINE | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1997-07-02 | — | — | EP | disclosed |
| EP-0289262-A2 | Omega-quaternary ammonium alkyl esters and thioesters of acidic nonsteroidal antiinflammatory drugs | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1988-11-02 | — | — | EP | disclosed |
| US-4455168-A | CONTAINING A HETEROCYCLIC, HYDROXY AMINE OR AMIDE | RICOH COMPANY, LTD. (JP) | 1984-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | PLTP, LNPEP, PLIN3 | HRH3 2171/4885CYP1A2 4878/4885MAPK1 4305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.